Clinical Trial Detail

NCT ID NCT01896999
Title Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Ipilimumab

Age Groups: adult

No variant requirements are available.